• Oragenics started enrolling and dosing patients in its Phase IIa, placebo-controlled feasibility study of intranasal concussion treatment ONP-002 in Australia, with a 40-patient target.
• Early execution signals included site activations at Mackay Base Hospital and Alfred Hospital, with Royal Adelaide Hospital expected to come online near term.
• No serious adverse events have been recorded so far, supporting continued enrollment and follow-up testing.
• Trial results have not yet been presented; a Phase IIa data readout is scheduled for 2026.
• Separately, an LOI was signed to pursue a license for a CNS-related medical device, aiming to broaden the company’s CNS platform beyond ONP-002.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180830PRIMZONEFULLFEED9722011) on May 18, 2026, and is solely responsible for the information contained therein.